Dr Reuben Benjamin Academics Clinical Senior Lecturer Contact details reuben.benjamin@kcl.ac.uk 02032994607
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation Allogeneic car-t cells: More than ease of access? Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Secondary HLH is uncommon in severe COVID-19 Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience Monitoring Allogeneic CAR-T Cells Using Flow Cytometry What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: A multi-centre UK experience Registry based retrospective analysis of bendamustine conditioned autologous hematopoietic stem cell transplants in myeloma Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant haematological disorders View all publications
24 February 2023 New CAR T-cell immunotherapy shows promising results for treating blood cancer patients The CALM clinical trial has highlighted the therapeutic potential of UCART19 and other…